|
Tell Your Story
Thanks all. You make such good points about the numbers etc. I agree that the Campath trial might owe its success rate to who they let in. My leaning towards it is because it DOES have a decent response rate with people like me and it seems less toxic.
But all this might be moot now. I got a call from NIH today saying that my last BMB showed a chromosome abnormality in one of 20 cells they studied --is this del(5q)? They want me to get another BMB to recheck before I come for the treatment.
They also told me that if I do the campath, I would be getting it subcutaneously instead of by infusion, which means no hospital stay (I'm embarrassed to admit I kinda was looking forward to being coddled inside NIH)
The doctor mentioned revlimid as the tx if more cells show the abnormality. What do you all know about that?
I appreciate you so much -- and I don't mind questions at all. I just don't always have the answers. A bit more info is that my cellularity is 20% and my blasts were <5%
|